9H-pyreno<1,2-b>pyran-9-one | 115560-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芘
• 英文名称: 9H-pyreno<1,2-b>pyran-9-one
• 英文别名: 10-Oxabenzo[def]chrysen-9-one；pyreno[1,2-b]pyran-9-one
• CAS: 115560-47-9
• 化学式: C₁₉H₁₀O₂
• 分子量: 270.287
• InChiKey: NHGPSFSQAVBCRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-羟基芘 在 正丁基锂 、 四甲基乙二胺 、 4 A molecular sieve 、 对甲苯磺酸 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 二氯甲烷 为溶剂， 反应 61.25h， 生成 9H-pyreno<1,2-b>pyran-9-one
  参考文献：
  名称：

  A new coumarin synthesis and its utilization for the synthesis of polycyclic coumarin compounds with anticarcinogenic properties

  摘要：

  DOI：

  10.1021/jo00252a011

文献信息

• Cytidine deaminase expression level in cancer as a new therapeutic target
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US11209421B2

  公开（公告）日：2021-12-28

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.

  本发明提供了一种选择肿瘤患者接受抗肿瘤化合物治疗的体外方法，其中该方法包括测量所述患者的癌症样本中CDA（胞苷脱氨酶）的表达水平的步骤。当癌症样本的CDA表达水平低于参考表达水平时，表明患者适合使用选自表4化合物组成的组的抗肿瘤化合物，特别是氨基黄酮进行治疗。或者，当癌症样本的CDA表达水平高于参考表达水平时，表明患者适合使用选自表3化合物组成的组的抗肿瘤化合物，特别是达沙替尼进行治疗。
• A new coumarin synthesis based on the aromatic metalation reaction
  作者：Ronald G. Harvey、Cecilia Cortez、T.P. Ananthanarayan、Sanford Schmolka

  DOI：10.1016/s0040-4039(00)61828-2

  日期：1987.1
• HARVEY, RONALD G.;CORTEZ, CECILLIA;ANANTHANARAVAN, T. P.;SCHMOLKA, SANFOR+, TETRAHEDRON LETT., 28,(1987) N 49, 6137-6138
  作者：HARVEY, RONALD G.、CORTEZ, CECILLIA、ANANTHANARAVAN, T. P.、SCHMOLKA, SANFOR+

  DOI：——

  日期：——
• CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET
  申请人：Centre National de la Recherche Scientifique

  公开号：EP3436601A1

  公开（公告）日：2019-02-06
• [EN] CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET<br/>[FR] NIVEAU D'EXPRESSION DE LA CYTIDINE DÉSAMINASE DANS UN CANCER EN TANT QUE NOUVELLE CIBLE THÉRAPEUTIQUE
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2017167989A1

  公开（公告）日：2017-10-05

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.